Trial results presented at US oncology conference suggest ribociclib could be gamechanging and boost survival rate significantly
Thousands of women with the world’s most common form of breast cancer could benefit from a blockbuster drug that helps them live longer and cuts the risk of the disease returning by a quarter.
More than 2 million people globally are diagnosed each year with the disease, which is the world’s most prevalent cancer. Although treatments have improved in recent decades, many patients will later experience the cancer returning. If a recurrence does occur, it is often at a more advanced stage.
About Author
More Stories
Scientists find ‘mutant’ gene behind foul-smelling species of wild ginger
The Guardian view on drought warnings: risks to the food supply need confronting | Editorial
Meta blocks major Muslim Instagram page in India amid rising conflict